Skip to main
GH
GH logo

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 46%
Buy 54%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health, Inc. demonstrated strong financial performance in 2024, achieving a 31% year-over-year revenue growth and exceeding expectations with fourth-quarter revenues of $202 million, reflecting a 30% increase from the previous year. The company's adjusted gross margin improved to 63%, supported by favorable reimbursement trends and an increase in the Guardant360 LDT Medicare rate, which is projected to boost revenues further. Additionally, with clinical volumes rising by 24% year-over-year and ongoing advancements in product offerings, including the FDA approval of the Shield test for colorectal cancer screening, Guardant is well-positioned for continued growth in the oncology market.

Bears say

Guardant Health faces several fundamental challenges that contribute to a negative outlook on its stock. The slower-than-anticipated growth of its therapy selection franchise, coupled with weaker-than-estimated adoption rates for its MRD testing and the potential for the Shield test to be excluded from the USPSTF guidelines, poses significant risks to its revenue projections. Furthermore, downward pressure on the average selling price (ASP) of Shield, competitive market dynamics, and difficulties in securing reimbursement for its tests underscore the financial uncertainties affecting the company's future performance.

GH has been analyzed by 26 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 54% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 26 analysts, GH has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.